



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



L-168,049

Item No. 41112

CAS Registry No.: 191034-25-0
Formal Name: 4-[3-(5-bromo-2-propoxyphenyl)-5-(4-chlorophenyl)-1H-pyrrol-2-yl]-pyridine
Synonyms: GCGR Antagonist II, Glucagon Receptor Antagonist II,
MF: C₂₄H₂₀BrClN₂O
FW: 467.8
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

L-168,049 is supplied as a solid. A stock solution may be made by dissolving the L-168,049 in the solvent of choice, which should be purged with an inert gas. L-168,049 is soluble (≥10 mg/ml) in ethanol and DMSO.

Description

L-168,049 is a glucagon receptor (GCGR) antagonist (IC₅₀s = 3.7 and 179 nM in the absence and presence of MgCl₂, respectively).¹ It prevents glucagon-induced increases in IL-1β and IL-6 levels in, and levels secreted from, HepG2 cells when used at a concentration of 3.7 nM.² L-168,049 inhibits glucagon-induced increases in the mRNA encoding complement 3 (C3), C-reactive protein (CRP), and fibrinogen in HepG2 cells. *In vivo*, L-168,049 (1 μM in drinking water) inhibits glucagon-induced increases in the hepatic levels of NOD-like receptor protein 3 (NLRP3), phosphorylated NF-κB, and phosphorylated Stat3 in mice.

References

1. Cascieri, M.A., Koch, G.E., Ber, E., *et al.* Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. *J. Biol. Chem.* **274**(13), 8694-8697 (1999).
2. Andreozzi, F., Di Fatta, C., Spiga, R., *et al.* Glucagon induces the hepatic expression of inflammatory markers in vitro and in vivo. *Diabetes Obes. Metab.* **25**(2), 556-569 (2023).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/25/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM